CIT-801
/ Cureimmune Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 11, 2021
[VIRTUAL] CIT-801: a bifunctional anti-PD1xIL15 agent demonstrated synergy and enhanced in vivo anti-tumor efficacy
(AACR 2021)
- "In a syngeneic MC38 tumor model with human-PD1 knock-in mice, the bifunctional anti-PD1xIL15 agent strongly inhibited tumor growth, superior to anti-PD1 antibody treatment alone. In summary, anti-PD1xIL15 bifunctional compound CIT-801 has shown a great therapeutic potential and is worth further development."
Preclinical • Oncology • IL15
April 07, 2021
"cytokine localization (no mask needed) 1879 - CIT-801: a bifunctional anti-PD1xIL15 agent demonstrated synergy and enhanced in vivo anti-tumor efficacy #AACR21 CureImmune Therapeutics"
(@PDRennert)
Preclinical • Oncology
1 to 2
Of
2
Go to page
1